FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
June 07, 2024 at 18:20 PM EDT
The FDA's expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and Moderna.
